Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antidepressant drugs: - **Amitriptyline** is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the central nervous system. It is primarily used for major depressive disorder, neuropathic pain, migraine prophylaxis, and other off-label uses[8]. - **Clovoxamine** is an antidepressant with both selective serotonin reuptake inhibitor (SSRI) and some noradrenergic activity. It has been used in some countries for depression and anxiety disorders. - **Fluvoxamine** is a selective serotonin reuptake inhibitor (SSRI), mainly indicated for obsessive-compulsive disorder but also used off-label for depression[5]. Fluvoxamine increases synaptic serotonin by inhibiting its reuptake. Combining these agents may theoretically enhance antidepressant efficacy due to complementary mechanisms on serotonergic and noradrenergic neurotransmission. However, such combinations are rarely standard practice due to significant risks of pharmacokinetic interactions—especially between fluvoxamine and amitriptyline—and increased risk of adverse effects including serotonin syndrome[1][2][3][4][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline + clovoxamine + fluvoxamine.